Lunit Inc. (328130.KQ) stock: key figures, P/E, revenue and dividend

Health Care · Health Care Equipment · South Korea

Price
15,850.00 KRW
Market cap
1.18 tn KRW
P/E (2025)
–
P/S (2025)
14.20
Dividend yield
0.00 %
Net margin
-57.01 %
Return on equity (ROE)
-34.48 %
Return on assets (ROA)
-12.81 %

Lunit Inc. financials

Fiscal year20242025
Revenue54.18 bn KRW83.13 bn KRW
Gross profit53.91 bn KRW83.13 bn KRW
Operating income-67.67 bn KRW-83.12 bn KRW
EBIT-69.80 bn KRW-21.12 bn KRW
Net income-82.42 bn KRW-47.39 bn KRW
Diluted EPS – continuing operations-2,854.58 KRW-756.63 KRW

Full history since 2019, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Lunit Inc.

Lunit Inc. provides AI-powered software and solutions for cancer diagnostics and therapeutics in South Korea. It offers AI solution for chest X-ray and mammography, as well as AI solution for digital breast tomosynthesis, and AI-powered biomarker for immune phenotyping and PD-L1 biomarker analyzer. The company has a strategic collaboration with AstraZeneca for the development of Lunit SCOPE Genotype Predictor, an AI-powered tool capable of analyzing H&E slide images to predict the likelihood of the tumor harboring NSCLC driver mutations, such as Epidermal Growth Factor Receptor mutations; with Agilent Technologies Inc. to create advanced solutions that meet the demand of novel and complex biomarker assays in drug development; and with Daiichi Sankyo Company, Limited to accelerate biomarker discovery and translational research. Lunit Inc. was founded in 2013 and is based in Seoul, South Korea.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.